GLAXOSMITHKLINE PLC Form 6-K October 11, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 11 October 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

b) Position / status

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Ms E Walmsley
b)	Position / status	Chief Executive Officer
c)	Initial notification / amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where $transaction(s)$ has been conducted	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.1765 8 (partnership shares) £15.1765 8 (matching shares)
	Aggregated information	
d)	Aggregated volume Price	16 Ordinary Shares £15.1765
e)	Date of the transaction	2017-10-10
f)	Place of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Mr R G Connor

President, Global Manufacturing

& Supply

c) Initial notification / amendment

Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

5493000HZTVUYLO1D793 b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.1765 9 (partnership shares)

£15.1765 9 (matching shares)

Aggregated information

b) Nature of the transaction

18 Ordinary Shares Aggregated volume

£15.1765 Price

2017-10-10 e) Date of the transaction

Place of the transaction London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Mr S Dingemans a) Name

Chief Financial Officer b) Position / status

Initial notification c) Initial notification / amendment

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

5493000HZTVUYLO1D793

b) LEI

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

a) Description of the financial instrument ('Ordinary Shares') ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.1765 9 (partnership shares)

£15.1765 9 (matching shares)

Aggregated information

d) Aggregated volume 18 Ordinary Shares

Price £15.1765

e) Date of the transaction 2017-10-10

f) Place of the transaction London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position / status SVP, Global Ethics & Compliance

c) Initial notification / amendment Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793

b) LEI

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

a) Description of the financial instrument ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares under the Company's Share b) Nature of the transaction Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £15.1765 8 (partnership shares) £15.1765 8 (matching shares) Aggregated information 16 Ordinary Shares Aggregated volume £15.1765 Price 2017-10-10 e) Date of the transaction Place of the transaction f) London Stock Exchange (XLON) Details of PDMR/person closely associated with them ('PCA') Mr D S Redfern a) Name Chief Strategy Officer b) Position / status Initial notification c) Initial notification / amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor GlaxoSmithKline plc a) Name 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 **Acquisition of Ordinary Shares** under the Company's Share b) Nature of the transaction Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £15.1765 8 (partnership shares) £15.1765 8 (matching shares)

16 Ordinary Shares

d) Aggregated information

Aggregated volume

Price £15.1765

e) Date of the transaction

2017-10-10

Place of the transaction

London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Ms C Thomas a) Name

SVP, Human Resources b) Position / status

Initial notification c) Initial notification / amendment

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name

5493000HZTVUYLO1D793 b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

b) Nature of the transaction Reward Plan.

> Price(s) Volume(s)

£15.1765 8 (partnership shares) c) Price(s) and volume(s)

£15.1765 8 (matching shares)

Aggregated information

16 Ordinary Shares

Aggregated volume £15.1765

Price

2017-10-10

e) Date of the transaction

Place of the transaction f) London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr P C Thomson a) Name President, Global Affairs b) Position / status Initial notification c) Initial notification / amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor GlaxoSmithKline plc a) Name 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 **Acquisition of Ordinary Shares** under the Company's Share b) Nature of the transaction Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £15.1765 9 (partnership shares) £15.1765 9 (matching shares) Aggregated information 18 Ordinary Shares Aggregated volume £15.1765 Price 2017-10-10 e) Date of the transaction Place of the transaction London Stock Exchange (XLON) f) Details of PDMR/person closely associated with them ('PCA') 1. Dr P J T Vallance a) Name President, R&D b) Position / status Initial notification c) Initial notification / amendment 2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

GlaxoSmithKline plc a) Name 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 **Acquisition of Ordinary Shares** under the Company's Share b) Nature of the transaction Reward Plan. Price(s) Volume(s) c) Price(s) and volume(s) £15.1765 8 (partnership shares) £15.1765 8 (matching shares) Aggregated information 16 Ordinary Shares Aggregated volume £15.1765 Price 2017-10-10 e) Date of the transaction Place of the transaction f) London Stock Exchange (XLON) Details of PDMR/person closely associated with them ('PCA') Mrs V A Whyte a) Name Company Secretary b) Position / status Initial notification c) Initial notification / amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor GlaxoSmithKline plc a) Name 5493000HZTVUYLO1D793 b) LEI

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.1765 9 (partnership shares)

£15.1765 9 (matching shares)

Aggregated information

b) Nature of the transaction

18 Ordinary Shares

Aggregated volume

£15.1765

Price

d)

2017-10-10

e) Date of the transaction Place of the transaction

London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: October 11, 2017

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on behalf of GlaxoSmithKline plc